Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensatinib in adjuvant ALK-positive NSCLC
NCT05186506Phase 2Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Sichuan University. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05186506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186506.